UK says new study vindicates delaying 2nd virus vaccine shot - Delta-Optimist | Canada News Media
Connect with us

Health

UK says new study vindicates delaying 2nd virus vaccine shot – Delta-Optimist

Published

 on


LONDON — Britain’s health chief has hailed a new study suggesting that a single dose of the Oxford-AstraZeneca COVID-19 vaccine provides a high level of protection for 12 weeks, saying it supports the government’s contentious strategy of delaying the second shot so it can protect more people quickly with a first dose.

Britain’s decision has been criticized as risky by other European countries, but Health Secretary Matt Hancock said Wednesday that the study “backs the strategy that we’ve taken and it shows the world that the Oxford vaccine works effectively.”

Hancock’s comments came after Oxford University released a study showing the vaccine cut transmission of the virus by two-thirds and prevented severe disease.

Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca, said no patients experienced severe COVID-19 or required hospitalization three weeks after receiving a first dose, and that efficacy appeared to increase up to 12 weeks after the initial shot.

“Our data suggest you want to be as close to the 12 weeks as you can” for the second dose, Pangalos said during a news conference.

The study has not been peer-reviewed yet, and it did not address dosing of the Pfizer-BioNTech vaccine, the other one currently in use in the U.K. Pfizer recommends that its shots be given 21 days apart and has not endorsed the U.K. government’s decision to lengthen the time between doses.

But the Oxford research was greeted with excitement by U.K. officials under pressure to justify their decision to delay the second dose.

“That reduction in transmission, as well as the fact there is no hospitalizations, the combination of that is very good news. And it categorically supports the strategy we’ve been taking on having a 12-week gap between the doses,” Hancock told Sky News.

Some countries, including France, have authorized the AstraZeneca vaccine only for use in people under 65, saying there is not enough evidence to say whether it works in older adults. Belgium has authorized it only for people 55 and under.

Yet one of the lead researchers on the Oxford vaccine project, Dr. Andrew Pollard, said “we expect it to be highly effective in older adults” and said more data should be available in the next few weeks.

Pangalos noted that the European Medicines Agency had authorized the vaccine for use in all people over age 18.

“How individual countries decide to implement vaccines is ultimately up to them based on the vaccine supplies that they have,” he said.

Vaccine supply is a sensitive issue in the European Union, which is unhappy that AstraZeneca cut back on the number of doses it plans to supply the EU with in the near term. The company said last month that it planned to cut initial deliveries within the EU from 80 million doses to 31 million doses due to reduced yields from its manufacturing plants in Europe.

It has since applied to supply 9 million additional doses to the 27-nation bloc, whose leaders are facing criticism over what is perceived as slow progress in inoculating the population.

Britain has Europe’s deadliest coronavirus outbreak, with more than 108,000 deaths, and is in its third national lockdown as authorities try to contain a new, more transmissible virus variant first identified in southeast England.

Other variants are also a concern. Public health officials in England are going door to door, trying to test all adults in eight targeted communities in an attempt to stop a new strain first identified in South Africa from spreading further.

So far 105 cases of the variant have been identified in the U.K., 11 of them in people with no links to overseas travel. Scientists say there’s no evidence the South African variant is more serious than the original virus but it may be more contagious. There are also concerns that current vaccines may be less effective against that variant because it contains a mutation of the virus’ characteristic spike protein that existing vaccines target.

That is a worry as the U.K. races to vaccinate its own population against the virus. Almost 10 million people have received the first of their two shots, including the bulk of people over 80 and those in nursing homes.

Pollard said Oxford scientists believe the AstraZeneca vaccine will continue to offer protection against new variants of COVID-19, although they are still waiting for data on that.

He said even if the virus adapts “that doesn’t mean that we won’t still have protection against severe disease.’’

“If we do need to update the vaccines, then it is actually a relatively straightforward process. It only takes a matter of months, rather than the huge efforts that everyone went through last year to get the very large-scale trials run,” he told the BBC.

___

Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak

Danica Kirka And Jill Lawless, The Associated Press






Let’s block ads! (Why?)



Source link

Continue Reading

Health

Canada to donate up to 200,000 vaccine doses to combat mpox outbreaks in Africa

Published

 on

 

The Canadian government says it will donate up to 200,000 vaccine doses to fight the mpox outbreak in Congo and other African countries.

It says the donated doses of Imvamune will come from Canada’s existing supply and will not affect the country’s preparedness for mpox cases in this country.

Minister of Health Mark Holland says the donation “will help to protect those in the most affected regions of Africa and will help prevent further spread of the virus.”

Dr. Madhukar Pai, Canada research chair in epidemiology and global health, says although the donation is welcome, it is a very small portion of the estimated 10 million vaccine doses needed to control the outbreak.

Vaccine donations from wealthier countries have only recently started arriving in Africa, almost a month after the World Health Organization declared the mpox outbreak a public health emergency of international concern.

A few days after the declaration in August, Global Affairs Canada announced a contribution of $1 million for mpox surveillance, diagnostic tools, research and community awareness in Africa.

On Thursday, the Africa Centres for Disease Control and Prevention said mpox is still on the rise and that testing rates are “insufficient” across the continent.

Jason Kindrachuk, Canada research chair in emerging viruses at the University of Manitoba, said donating vaccines, in addition to supporting surveillance and diagnostic tests, is “massively important.”

But Kindrachuk, who has worked on the ground in Congo during the epidemic, also said that the international response to the mpox outbreak is “better late than never (but) better never late.”

“It would have been fantastic for us globally to not be in this position by having provided doses a much, much longer time prior than when we are,” he said, noting that the outbreak of clade I mpox in Congo started in early 2023.

Clade II mpox, endemic in regions of West Africa, came to the world’s attention even earlier — in 2022 — as that strain of virus spread to other countries, including Canada.

Two doses are recommended for mpox vaccination, so the donation may only benefit 100,000 people, Pai said.

Pai questioned whether Canada is contributing enough, as the federal government hasn’t said what percentage of its mpox vaccine stockpile it is donating.

“Small donations are simply not going to help end this crisis. We need to show greater solidarity and support,” he said in an email.

“That is the biggest lesson from the COVID-19 pandemic — our collective safety is tied with that of other nations.”

This report by The Canadian Press was first published Sept. 13, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

How many Nova Scotians are on the doctor wait-list? Number hit 160,000 in June

Published

 on

 

HALIFAX – The Nova Scotia government says it could be months before it reveals how many people are on the wait-list for a family doctor.

The head of the province’s health authority told reporters Wednesday that the government won’t release updated data until the 160,000 people who were on the wait-list in June are contacted to verify whether they still need primary care.

Karen Oldfield said Nova Scotia Health is working on validating the primary care wait-list data before posting new numbers, and that work may take a matter of months. The most recent public wait-list figures are from June 1, when 160,234 people, or about 16 per cent of the population, were on it.

“It’s going to take time to make 160,000 calls,” Oldfield said. “We are not talking weeks, we are talking months.”

The interim CEO and president of Nova Scotia Health said people on the list are being asked where they live, whether they still need a family doctor, and to give an update on their health.

A spokesperson with the province’s Health Department says the government and its health authority are “working hard” to turn the wait-list registry into a useful tool, adding that the data will be shared once it is validated.

Nova Scotia’s NDP are calling on Premier Tim Houston to immediately release statistics on how many people are looking for a family doctor. On Tuesday, the NDP introduced a bill that would require the health minister to make the number public every month.

“It is unacceptable for the list to be more than three months out of date,” NDP Leader Claudia Chender said Tuesday.

Chender said releasing this data regularly is vital so Nova Scotians can track the government’s progress on its main 2021 campaign promise: fixing health care.

The number of people in need of a family doctor has more than doubled between the 2021 summer election campaign and June 2024. Since September 2021 about 300 doctors have been added to the provincial health system, the Health Department said.

“We’ll know if Tim Houston is keeping his 2021 election promise to fix health care when Nova Scotians are attached to primary care,” Chender said.

This report by The Canadian Press was first published Sept. 11, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Newfoundland and Labrador monitoring rise in whooping cough cases: medical officer

Published

 on

 

ST. JOHN’S, N.L. – Newfoundland and Labrador‘s chief medical officer is monitoring the rise of whooping cough infections across the province as cases of the highly contagious disease continue to grow across Canada.

Dr. Janice Fitzgerald says that so far this year, the province has recorded 230 confirmed cases of the vaccine-preventable respiratory tract infection, also known as pertussis.

Late last month, Quebec reported more than 11,000 cases during the same time period, while Ontario counted 470 cases, well above the five-year average of 98. In Quebec, the majority of patients are between the ages of 10 and 14.

Meanwhile, New Brunswick has declared a whooping cough outbreak across the province. A total of 141 cases were reported by last month, exceeding the five-year average of 34.

The disease can lead to severe complications among vulnerable populations including infants, who are at the highest risk of suffering from complications like pneumonia and seizures. Symptoms may start with a runny nose, mild fever and cough, then progress to severe coughing accompanied by a distinctive “whooping” sound during inhalation.

“The public, especially pregnant people and those in close contact with infants, are encouraged to be aware of symptoms related to pertussis and to ensure vaccinations are up to date,” Newfoundland and Labrador’s Health Department said in a statement.

Whooping cough can be treated with antibiotics, but vaccination is the most effective way to control the spread of the disease. As a result, the province has expanded immunization efforts this school year. While booster doses are already offered in Grade 9, the vaccine is now being offered to Grade 8 students as well.

Public health officials say whooping cough is a cyclical disease that increases every two to five or six years.

Meanwhile, New Brunswick’s acting chief medical officer of health expects the current case count to get worse before tapering off.

A rise in whooping cough cases has also been reported in the United States and elsewhere. The Pan American Health Organization issued an alert in July encouraging countries to ramp up their surveillance and vaccination coverage.

This report by The Canadian Press was first published Sept. 10, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version